Ensuring Access to Optimal Therapy in CF: The ENACT Study

This study will examine different dosing strategies and outcomes for triple combination CFTR modulator therapy using the drug(s) elexacaftor, tezacaftor, and/or ivacaftor in patients with cystic fibrosis.

Participants who consent to the therapeutic drug monitoring study will have their dose adjusted to remain within estimated effective concentrations.